



Epilepsy Research and Antiepileptic Drugs, 2nd Edition

Guest Editor:

Dr. Sonia Mayo

Genetics and Inheritance
Research Group, Instituto de
Investigación Sanitaria Hospital
12 de Octubre, 28041 Madrid,
Spain

Deadline for manuscript
submissions:

closed (20 August 2025)

Message from the Guest Editor

Approximately 30% of Epileptic patients present refractory epilepsy (RE), defined as “failure of adequate trials of two tolerated and appropriately chosen and used anti-seizure medication schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom”. In up to 70–80% of the cases, some genetic component is present. Hundreds of genes are known to be involved in epilepsy, and the number continues to rise. For this reason, the use of screening techniques such as whole-exome sequencing (WES) and/or whole-genome sequencing (WGS) has allowed the identification of new pathological genes and, in many cases, molecular diagnosis. Although drug resistance in epilepsy is likely to be multifactorial, the molecular mechanisms underlying it are poorly understood. It remains impossible to explain why only some patients with the same type of epilepsy and matching etiologies develop refractory epilepsy after treatment. This Special Issue, entitled “Epilepsy Research and Antiepileptic Drugs 2.0”, will continue the work of previous publications on the etiology of epilepsy, with an especial focus on refractory epilepsy.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. José L. Quiles

Department of Physiology,
Institute of Nutrition and Food
Technology “Jose Mataix”,
Biomedical Research Center,
University of Granada, Avda.
Conocimiento s/n, 18100 Armilla,
Granada, Spain

Message from the Editor-in-Chief

The *International Journal of Molecular Sciences (IJMS)* is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, and molecular biophysics. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Contact Us

*International Journal of Molecular
Sciences* Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/ijms
ijms@mdpi.com
X@IJMS_MDPI